22 May 2013
Keywords: abbott, ra, drug, humira, potential, therapy, crohn
Article | 07 February 2005
Patients with active Crohn's disease who have ceased responding to Johnson & Johnson and Schering-Plough's Remicade (infliximab) may
respond to Abbott ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
7 February 2005
31 January 2005
14 February 2005
© 2013 thepharmaletter.com